Últimas noticias sobre Cardinal Health (NYSE:CAH) Bolsa

Cardinal Health

Cardinal Health is one of three leading pharmaceutical wholesalers in the US, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. Cardinal, Cencora, and McKesson hold well over 90% of the US pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

CSCO

OUST

SERV

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este miércoles: EAT, SERV, CSCO, OUST y CAH.

5 acciones en el foco este miércoles: EAT, SERV, CSCO, OUST y CAH

Cardinal Health Inc

CARRIER ALLIANCE HLDGS by Carrier Alliance Holdings, Inc.

Carrier Alliance Holdings Inc

CELESTIAL ASIA SECS NEW by Celestial Asia Secs Holdings Ltd.

Celestial Asia Securities Holdings Ltd

Caro Holdings Inc

EVOLUTION MINING LTD ORD by Evolution Mining Ltd.

Evolution Mining Ltd

Morgan Stanley analyst Erin Wright maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Overweight and raises the price target from $136 to $142.

Price Target

Analyst Ratings

Morgan Stanley Maintains Overweight on Cardinal Health, Raises Price Target to $142

Guidance

Cardinal Health Raises FY25 Non-GAAP EPS Guidance From $7.75-$7.90 To $7.85-$8.00 vs $7.86 Est.

Earnings Beats

Cardinal Health Q2 2025 Adj. EPS $1.93 Beats $1.76 Estimate, Sales $55.3B Beat $54.915B Estimate

AAPL

ABCB

ALGM

APPF

Adtalem Global Education Inc. Common Stock

ATGE

BAFN

BBVA

BHLB

BOOT

CACC

CHKP

CIVB

CMCSA

CNOB

COUR

CSWI

CVCO

DECK

FBIZ

FCFS

FFWM

FINW

FISI

FLWS

FRME

GSIT

INTC

KLAC

KRNY

LPLA

MBLY

MBUU

NTCT

ONEW

PFSI

REAL

SCSC

SHEL

SILC

SIRI

SKYW

STBA

STEL

Earnings Scheduled For January 30, 2025

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Truist Securities raised the price target for Tempur Sealy International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPX#NYSE">TPX</a>) from $63 to $69. Truist Securities analyst Keith Hughes maintained a Buy rating. Tempur Sealy shares closed at $60.62 on Tuesday. <a href="https://www.benzinga.com/quote/TPX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan cut Nucor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) price target from $152 to $150. JP Morgan analyst Bill Peterson maintained an Overweight rating. Nucor shares closed at $126.55 on Tuesday. <a href="https://www.benzinga.com/quote/NUE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Scotiabank cut the price target for NextEra Energy Partners, LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEP#NYSE">NEP</a>) from $15 to $12. Scotiabank analyst Andrew Weisel maintained a Sector Perform rating. NextEra Energy Partners shares closed at $11.83 on Tuesday. <a href="https://www.benzinga.com/quote/NEP/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Argus Research raised the price target for Royal Caribbean Cruises Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) from $280 to $305. Argus Research analyst John Staszak maintained a Buy rating. Royal Caribbean Cruises shares closed at $265.25 on Tuesday. <a href="https://www.benzinga.com/quote/JNJ/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stifel boosted Stryker Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) price target from $400 to $450. Stifel analyst Rick Wise maintained a Buy rating. Stryker shares settled at $395.15 on Tuesday. <a href="https://www.benzinga.com/quote/SYK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities cut Lyft, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) price target from $21 to $19. B of A Securities analyst Michael McGovern maintained a Buy rating. Lyft shares closed at $13.96 on Tuesday. <a href="https://www.benzinga.com/quote/LYFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan lifted RTX Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) price target from $140 to $150. JP Morgan analyst Seth Seifman maintained an Overweight rating. RTX shares closed at $128.35 on Tuesday.  <a href="https://www.benzinga.com/quote/RTX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham boosted the price target for F5, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>) from $285 to $360. Needham analyst Matt Dezort maintained a Buy rating. F5 shares settled at $269.72 on Tuesday. <a href="https://www.benzinga.com/quote/FFIV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo boosted Cardinal Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) price target from $127 to $135. Wells Fargo analyst Stephen Baxter maintained an Equal-Weight rating. Cardinal Health shares closed at $126.27 on Tuesday. <a href="https://www.benzinga.com/quote/CAH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays increased Starbucks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) price target from $119 to $124. Barclays analyst Jeffrey Bernstein maintained an Overweight rating. Starbucks shares closed at $100.41 on Tuesday. <a href="https://www.benzinga.com/quote/SBUX/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43301090/how-to-earn-500-a-month-from-meta-platforms-stock-ahead-of-q4-earnings">How To Earn $500 A Month From Meta Platforms Stock Ahead Of Q4 Earnings</a></li>
</ul>

FFIV

LYFT

SBUX

Starbucks To Rally Over 23%? Here Are 10 Top Analyst Forecasts For Wednesday

Note: This story has been updated with additional details on recent moves by tech titans.
Rep. Marjorie Taylor Greene (R-Ga.) <a href="https://www.benzinga.com/insights/government/25/01/43271358/georgia-rep-marjorie-taylor-greene-bought-over-1k-worth-of-asml-holding-stock-heres-what-you-">disclosed</a> a series of new trades as President Donald Trump&#8216;s equations with the leaders of Big Tech companies and other firms evolve during his second term. Greene&#8217;s portfolio shows the addition of 14 stocks and U.S. Treasuries, in a disclosure dated Jan. 27.
What Happened: The Republican politician, Greene, who has been the representative of Georgia&#8217;s 14th congressional district since 2021 has added a total of five lots of Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and Advanced Micro Devices Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), with a transaction value of $1,001-$15,000 each to her portfolio in 2025, with the most recent trade on Jan. 21.
According to Benzinga&#8217;s government trades <a href="https://www.benzinga.com/gov-trades/members/marjorie-taylor-greene">tracking tool</a>, Taylor Greene also owns two lots of Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), with the recent purchase valued at $1,001-$15,000 on Jan. 21.
Whereas, Green purchased Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) and Visa Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) for the first time in 2025 on Jan. 21, valued at around $1,001-$15,000, ahead of the Federal Reserve&#8217;s interest rate decision
Here&#8217;s a summary of Greene&#8217;s trades on Jan. 21:
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Stocks/Bonds Purchased</td>
<td>Amount</td>
</tr>
<tr>
<td>Advanced Micro Devices Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>)</td>
<td>$1,001-$15,000</td>
</tr>
<tr>
<td>Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)</td>
<td>$1,001-$15,000</td>
</tr>
<tr>
<td>Cardinal Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>)</td>
<td>$1,001-$15,000</td>
</tr>
<tr>
<td>Devon Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>)</td>
<td>$1,001-$15,000</td>
</tr>
<tr>
<td>Eli Lilly And Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)</td>
<td>$1,001-$15,000</td>
</tr>
<tr>
<td>Kinder Morgan Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMI#NYSE">KMI</a>)</td>
<td>$1,001-$15,000</td>
</tr>
<tr>
<td>Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)</td>
<td>$1,001-$15,000</td>
</tr>
<tr>
<td>NextEra Energy Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>)</td>
<td>$1,001-$15,000</td>
</tr>
<tr>
<td>Norfolk Southern Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>)</td>
<td>$1,001-$15,000</td>
</tr>
<tr>
<td>Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</td>
<td>$1,001-$15,000</td>
</tr>
<tr>
<td>Occidental Petroleum Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>)</td>
<td>$1,001-$15,000</td>
</tr>
<tr>
<td>Old Dominion Freight Line Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>)</td>
<td>$1,001-$15,000</td>
</tr>
<tr>
<td>Palo Alto Networks Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>)</td>
<td>$1,001-$15,000</td>
</tr>
<tr>
<td>Visa Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>)</td>
<td>$1,001-$15,000</td>
</tr>
<tr>
<td>US Treasury Bills</td>
<td>$50,001-$100,000</td>
</tr>
</tbody>
</table>
</figure>
While she owned two lots of Palo Alto Networks worth $1,001-$15,000 and one lot of U.S. Treasury bills worth $100,001-$250,000, all other purchases in the list are the most recent, dated Jan. 21.
See Also: <a href="https://www.benzinga.com/25/01/43295664/nvidia-supplier-asml-beats-q4-earnings-as-ceo-says-ai-is-key-driver-for-growth-is-it-a-buy-sell-or-hold-heres-what-technical-analysis-suggest">Nvidia Supplier ASML Beats Q4 Earnings Estimates, CEO Says &#8216;AI Is Key Driver For Growth:&#8217; Buy, Sell, Or Hold? Here&#8217;s What Technical Analysis Suggests </a>
Apart, from these stocks, she had investments worth $1,001-$15,000 in three lots of Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), Berkshire Hathaway Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>), and Caterpillar Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) in 2025.
She also held one lot worth $1,001-$15,000 in Home Depot Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>), iShares Bitcoin Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NASDAQ">IBIT</a>), Southern Copper Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCCO#NYSE">SCCO</a>), Hershey Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>), and two lots worth the same in United Parcel Service Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) and Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>), in 2025.
Lastly, in 2025, she owned four lots of the same amount in JPMorgan Chase &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) and Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>).
Why It Matters: Members of Congress, both senators and representatives must publicly <a href="https://www.benzinga.com/insights/government/25/01/43271358/georgia-rep-marjorie-taylor-greene-bought-over-1k-worth-of-asml-holding-stock-heres-what-you-">disclose</a> any personal stock trades they make. This means they have to file a report whenever they buy or sell stock.
The STOCK Act, which became law in 2012, requires these reports to be filed within 45 days of the transaction and also mandates monthly disclosures of their financial holdings. This law aims to prevent insider trading by making sure Congress members don&#8217;t use their privileged information for personal profit in the stock market.
Major tech titans, including Tesla&#8217;s Elon Musk, Amazon&#8217;s Jeff Bezos, Meta&#8217;s Mark Zuckerberg, Apple&#8217;s Tim Cook, And Google&#8217;s Sundar Pichai have been visiting President <a href="https://www.benzinga.com/news/25/01/42935628/mark-zuckerberg-meets-donald-trump-at-mar-a-lago-mending-fences-ahead-of-gop-white-house-return">Trump's Mar-a-Lago </a>residence, reportedly seeking to shape future tech policies. 
Following Trump's victory in the 2024 U.S. presidential election, major tech leaders are shifting their strategies to align with the new administration. Zuckerberg <a href="https://www.benzinga.com/tech/25/01/42779753/mark-zuckerbergs-meta-replaces-global-affairs-chief-nick-clegg-with-republican-joel-kaplan-ahead-of-trump-inauguration">appointed Republican</a> Joel Kaplan to lead policy and donated $1 million. Google, Amazon, and Apple followed suit with similar contributions. Microsoft's Satya Nadella, who reportedly gave $500,000 to Trump&#8217;s first inauguration, is also engaging with the new administration to strengthen relations.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43263070/deepseek-buzz-batters-big-tech-but-this-analyst-says-buy-the-dip-heres-a-list-of-top-five-semiconductor-etfs-with-the-lowest-expense-rations-that-investors-could-consider">DeepSeek Buzz Batters Big Tech But This Analyst Says &#8216;Buy The Dip:&#8217; Here&#8217;s Are Top 5 Semiconductor ETFs With The Lowest Expense Ratios That You Can Consider </a></li>
</ul>
Photo courtesy: Shutterstock

Equities

Market Summary

Sector ETFs

Bonds

Politics

ETFs

General

AMZN

GOOG

IBIT

NVDA

ODFL

PANW

SCCO

TSLA

Marjorie Taylor Greene Loads Up On Meta, Amazon, Tesla, Nvidia And Other Stocks As Donald Trump's New Equations With Big Tech Leaders Sets Stage For Growth: What Is At Stake? (UPDATED)

Wells Fargo analyst Stephen Baxter maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Equal-Weight and raises the price target from $127 to $135.

Wells Fargo Maintains Equal-Weight on Cardinal Health, Raises Price Target to $135

A January filing shows that Representative Marjorie Taylor Greene reported a purchase in Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>), valued between $1,001 and $15,000. The transaction date is listed as January 27, 2025, with the report published on January 27, 2025.
At present, Cardinal Health shares are trading down 0.03% at $130.69.
<h3>Representative's Recent Trading Activity</h3>
In the last three years, Marjorie Taylor Greene completed 163 stock transactions totaling more than $1.14 million. Costco Wholesale and Home Depot stocks were among the largest trades. Some of the most notable transactions the Rep. has executed recently include: 
<ul>
<li>Adobe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>): $1,001 - $15,000 Purchase</li>
<li>Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>): $1,001 - $15,000 Purchase</li>
<li>Applied Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>): $1,001 - $15,000 Purchase</li>
</ul>
Here's a summary of Marjorie Taylor Greene's recent trades:
<table>
<thead>
<tr>
<th>Company</th>
<th>Ticker</th>
<th>Stock Type</th>
<th>Amount</th>
<th>Transaction Type</th>
<th>Transaction Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adobe</td>
<td>ADBE</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2024-12-24</td>
</tr>
<tr>
<td>Amazon.com</td>
<td>AMZN</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2024-12-24</td>
</tr>
<tr>
<td>Applied Mat</td>
<td>AMAT</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2024-12-24</td>
</tr>
<tr>
<td>Caterpillar</td>
<td>CAT</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2024-12-24</td>
</tr>
<tr>
<td>Duke Energy</td>
<td>DUK</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2024-12-24</td>
</tr>
</tbody>
</table>
To stay updated on Marjorie Taylor Greene's trades and other congressional trades, try our <a href="https://www.benzinga.com/gov-trades/members/marjorie-taylor-greene">government trades tool</a> for live updates!
<h3>Why Congressional Transactions Matter</h3>
A congressional transaction is when any representative or senator either buys or sells an individual stock.
Anyone working in Congress must file a Periodic Transaction Report to inform the public of their recent transaction within 30 days of being notified of the transaction and within 45 days of the transaction date.
In April 2012, Former President Barack Obama signed the STOCK Act into law. The act prohibits members of Congress from using private information given to them by their position for personal gain such as buying or selling a stock. The act also expanded disclosure requirements for members of Congress by requiring them to file a monthly disclosure.
<h3>The Importance of Congressional Transactions</h3>
Congressional transactions shouldn't be the primary reason for an investing decision, but they can be an important factor for an investor to consider.
When a senator or representative makes a new purchase, it could be an indication they expect the stock to rise.
A sale, on the other hand, can be made for a variety of reasons, and may not necessarily mean the seller thinks the stock will go down.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Government

ADBE

AMAT

A Congress Member Bought Up To $15K In Cardinal Health Stock: Here's What You Need To Know

JP Morgan analyst Lisa Gill maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Neutral and raises the price target from $132 to $142.

JP Morgan Maintains Neutral on Cardinal Health, Raises Price Target to $142

<a href="https://www.wsj.com/articles/purdue-pharmas-sacklers-strike-new-6-5-billion-settlement-of-opioid-claims-1548617b" title="https://www.wsj.com/articles/purdue-pharmas-sacklers-strike-new-6-5-billion-settlement-of-opioid-claims-1548617b">https://www.wsj.com/articles/purdue-pharmas-sacklers-strike-new-6-5-billion-settlement-of-opioid-claims-1548617b</a>

Legal

'Purdue Pharma's Sacklers Strike New $6.5 Billion Settlement of Opioid Claims' - WSJ

Cardinal Health's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) short percent of float has fallen 26.84% since its last report. The company recently reported that it has 4.22 million shares sold short, which is 2.29% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.9 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Cardinal Health Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736873110_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Cardinal Health has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Cardinal Health's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Cardinal Health's peer group average for short interest as a percentage of float is 4.55%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(CAH) - Analyzing Cardinal Health's Short Interest

Cardinal Health, Inc. (the "Company") is providing an update to its previously announced expectations for non-GAAP diluted earnings per share ("non-GAAP EPS") for fiscal year 2025. The Company now expects fiscal year 2025 non-GAAP EPS to be toward the high end of its previously provided range of $7.75 to $7.90, primarily driven by continued strength within the Pharmaceutical and Specialty Solutions segment.

Cardinal Health Expects FY25 Adj EPS To Be Toward Higher End Of $7.75-$7.90 Vs $7.84 Est

Citigroup analyst Daniel Grosslight maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Neutral and raises the price target from $120 to $129.

Citigroup Maintains Neutral on Cardinal Health, Raises Price Target to $129

Editor&#8217;s Note: The story has been updated for improved clarity and readability.
On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer weighed in on stocks brought up by viewers, highlighting risks and opportunities in the market.
<h3 class="wp-block-heading">High Valuations Prompt Caution</h3>
Lemonade, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMND#NYSE">LMND</a>) has climbed significantly, prompting Cramer to caution, &#8220;up too much&#8230; You got to let it come down.&#8221; JMP Securities' Ronald Josey echoed similar concerns, maintaining a Market Outperform rating and raising the price target from $40 to $60 on Nov. 22.
<h3 class="wp-block-heading">Healthcare Stocks In Focus</h3>
Cencora, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) could &#8220;go lower,&#8221; Cramer said, preferring Cardinal Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) instead. Cencora has been expanding its portfolio, completing its acquisition of Retina Consultants of America on Jan. 2. The move strengthens its position in specialized healthcare.
For Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), Cramer advised caution, saying he would be &#8220;careful&#8221; with the stock. The company recently reported Phase 3 trial results for its <a href="https://www.benzinga.com/government/regulations/24/12/42623343/exclusive-weight-loss-market-experts-scoop-up-novo-nordisk-stock-after-worst-drop-since-2002-following-drug-trial-miss">CagriSema combination therap</a>y, which showed promising outcomes but the stock is down over 22% in the past month.
<h3 class="wp-block-heading">GLP-1 Impact on Consumer Staples</h3>
Cramer pointed out challenges for PepsiCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>), saying it's in the &#8220;crosshairs of the GLP-1 situation.&#8221; Despite this, Piper Sandler's Mike Lavery initiated coverage on Jan. 7 with an Overweight rating and a $171 price target, reflecting optimism for PepsiCo's resilience in response to shifting consumer trends.
Price Action:
<ul>
<li>Novo Nordisk shares fell 2% to settle at $83.34 on Tuesday.</li>
<li>PepsiCo shares fell 0.6% to close at $145.40 during the session.</li>
<li>Cencora shares gained 2.3% to settle at $234.24.</li>
<li>Lemonade shares fell 6.3% to settle at $36.14 on Tuesday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/01/42846607/bank-of-new-york-mellon-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">Bank of New York Mellon Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>
Image: Shutterstock

Long Ideas

Media

LMND

Jim Cramer: Lemonade Is 'Up Too Much,' This Health Care Stock Can Go Lower (UPDATED)

TD Cowen analyst Charles Rhyee upgrades Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) from Hold to Buy and raises the price target from $130 to $144.

Upgrades

TD Cowen Upgrades Cardinal Health to Buy, Raises Price Target to $144

BofA Securities predicts that headline risks affecting the Healthcare Tech &amp; Distribution sector in 2024 will likely continue in 2025.
Key areas of concern include pharmacy benefit managers (PBMs), retail pharmacies, distributors, fertility benefits, and direct-to-consumer (D2C) pharmacies.
While regulatory pressure on PBMs is expected to persist, the analyst believes this will mainly impact profit margins and growth rates rather than lead to major changes in the business model.
Potential policy shifts under the next administration could involve adjustments to the Inflation Reduction Act, expanded access to health savings accounts (HSAs), and increased support for fertility benefits.
BofA upgraded Cardinal Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) from <a target="_blank" href="https://www.benzinga.com/quote/CAH/analyst-ratings" rel="noreferrer noopener">Neutral to Buy</a>. The analyst notes Cardinal Health&#8217;s core pharmaceutical segment is growing faster than its competitors, with this trend expected to strengthen in the coming year.
Also Raed: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/41684029/cardinal-health-raises-2025-profit-outlook-again-helped-by-strong-drug-distribution-business" rel="noreferrer noopener">Cardinal Health Raises 2025 Profit Outlook Again, Helped By Strong Drug Distribution Business</a>
The company is benefiting from a unique advantage in its pharmacy benefit management (PBM) business, which could add 2-3 percentage points to earnings per share growth through fiscal 2026.
Despite its stronger growth potential, Cardinal&#8217;s stock is trading at a notable discount compared to McKesson Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>), but this gap is likely to close or reverse within the next year.
BofA has also upgraded Henry Schein (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) from <a target="_blank" href="https://www.benzinga.com/quote/HSIC/analyst-ratings" rel="noreferrer noopener">Underperform to Buy</a> and raised the price target from $69 to $84, recognizing it as a top-tier dental business poised for long-term earnings growth.
The company is recovering from last year&#8217;s cybersecurity incident, which should <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/41752173/henry-schein-q3-earnings-sees-recovery-from-cyber-incident-says-dental-equipment-business-shows-sta" rel="noreferrer noopener">boost reported figures</a>.
With these challenges behind it and expectations now more realistic, the analyst writes Henry Schein offers a strong opportunity to benefit from a recovering dental market.
The company could see additional upside in the medium to long term, driven by a shift toward private-label products and a growing focus on specialty services. The analyst notes the price target of $84 is reasonable given its position at a market low.
Price Action: At the last check Tuesday, CAH stock was up 0.61% at $120.36, and HSIC stock was down 0.08% at $71.70.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42853126/phillips-66-powers-up-with-22-billion-deal-for-epic-y-grades-ngl-business" target="_blank" rel="noreferrer noopener">Phillips 66 Powers Up With $2.2 Billion Deal For EPIC Y-Grade&#8217;s NGL Business</a></li>
</ul>
Photo by Casimiro PT via Shutterstock

Analyst Color

Large Cap

Health Care

HSIC

Headline Risks Affecting Healthcare Tech & Distribution Sector Will Likely Continue in 2025: BofA Analyst

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Evercore ISI Group analyst Elizabeth Anderson upgraded the rating for Cardinal Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) from In-Line to Outperform and maintained the price target of $140. Cardinal Health shares closed at $119.63 on Monday. <a href="https://www.benzinga.com/quote/CAH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan analyst Kenneth Worthington upgraded Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) from Underweight to Neutral and boosted the price target from $20 to $43. Robinhood shares closed at $42.71 on Monday. <a href="https://www.benzinga.com/quote/HOOD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Keybanc analyst Matthew Gillmor upgraded the rating for Acadia Healthcare Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) from Sector Weight to Overweight and announced a $70 price target. Acadia Healthcare shares closed at $44.85 on Monday. <a href="https://www.benzinga.com/quote/ACHC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Bernstein analyst Aneesha Sherman upgraded the rating for Lululemon Athletica Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) from Market Perform to Outperform. Lululemon shares closed at $395.31 on Monday. <a href="https://www.benzinga.com/quote/LULU/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Michael Turrin upgraded Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) from Equal-Weight to Overweight and raised the price target from $150 to $200. Snowflake shares closed at $163.08 on Monday. <a href="https://www.benzinga.com/quote/SNOW/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying HOOD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="603" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07085545/image-34-1024x603.png" alt="" class="wp-image-721866" style="width:586px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07085545/image-34-1024x603.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07085545/image-34-300x177.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07085545/image-34-768x452.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07085545/image-34.png 1155w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42839544/wells-fargo-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">Wells Fargo Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

ACHC

HOOD

LULU

SNOW

This Robinhood Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Tuesday

Evercore ISI Group analyst Elizabeth Anderson upgrades Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) from In-Line to Outperform and maintains the price target from $140 to $140.

Evercore ISI Group Upgrades Cardinal Health to Outperform, Maintains Price Target to $140

B of A Securities analyst Michael Cherny upgrades Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) from Neutral to Buy and raises the price target from $132 to $145.

B of A Securities Upgrades Cardinal Health to Buy, Raises Price Target to $145

Morgan Stanley analyst Erin Wright maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Overweight and raises the price target from $127 to $136.

Morgan Stanley Maintains Overweight on Cardinal Health, Raises Price Target to $136

Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS – MasterCard (MA) up 1% Blackstone (BX) up 1% T...

Morning Movers: UPS and Cigna plunge double digits following Q4 results

Cardinal Health, Inc. 2025 Q2 - Results - Earnings Call Presentation

Leerink raised the firm's price target on Cardinal Health (CAH) to $156 from $138 and keeps an Outperform rating on the shares. Q2 results "continu...

Cardinal Health price target raised to $156 from $138 at Leerink

Cardinal Health raises FY25 EPS guidance to $7.85-$8 amid specialty growth and acquisitions

Cardinal Health, Inc. (CAH) Q2 2025 Earnings Call Transcript

Charles Rhyee, an analyst from TD Cowen, maintained the Buy rating on Cardinal Health (CAH – Research Report). The associated price target was rais...

Positive Financial Prospects Drive Buy Rating for Cardinal Health Amid Raised Guidance and Strong Segment Performance

Mizuho Securities analyst Steven Valiquette has reiterated their bullish stance on CAH stock, giving a Buy rating yesterday. Steven Valiquette has ...

Cardinal Health's Strong Performance and Strategic Acquisitions Justify Buy Rating

Baird raised the firm's price target on Cardinal Health (CAH) to $154 from $149 and keeps an Outperform rating on the shares. Published first on Th...

Cardinal Health price target raised to $154 from $149 at Baird

Bank of America Securities analyst Allen Lutz maintained a Buy rating on Cardinal Health (CAH – Research Report) today. The company's shares closed...

Bank of America Securities Reaffirms Their Buy Rating on Cardinal Health (CAH)

Cardinal Health (($CAH)) has held its Q2 earnings call. Read on for the main highlights of the call. Cardinal Health's recent earnings call showcas...

Cardinal Health's Earnings Call: Growth Amid Challenges

MSFT

TSCO

Dividends

Press Releases

Cardinal Health Board of Directors Approves Quarterly Dividend

Cardinal Health announces two strategic additions to its portfolio

GI Alliance to Partner with Cardinal Health Creating a Scaled Multi-Specialty Managed-Services Platform to Benefit Physicians and Patients

Court Square Capital Partners Announces Sale of Advanced Diabetes Supply Group

Cardinal Health launches Kendall SCD SmartFlow™ Compression System

T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens

Cardinal Health to Announce Second-Quarter Results for Fiscal Year 2025 on January 30

RPM Announces Appointment of Three New Board Members

Cardinal Health to open new distribution center in Fort Worth, Texas

Cardinal Health Reports Second Quarter Fiscal Year 2025 Results and Raises Fiscal Year 2025 Outlook

Comments

Cardinal Health

Noticias

Últimas noticias sobre Cardinal Health (NYSE:CAH) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL